Volume 3, Issue 2, June 2019, Page: 43-45
Patient with Refractory Epilepsy Associated with Oligondendroglioma
Mauricio Vaillant Amarante, Department of Family and Community Health Strategy, Municipal Government of Domingos Martins, Domingos Martins, Espírito Santo, Brazil
Ozinelia Pedroni Batista, Department of Family and Community Health Strategy, Municipal Government of Domingos Martins, Domingos Martins, Espírito Santo, Brazil
Camilia Lampier Lutzke, Department of Family and Community Health Strategy, Municipal Government of Domingos Martins, Domingos Martins, Espírito Santo, Brazil
Shirley Kempin Quiqui, Department of Family and Community Health Strategy, Municipal Government of Domingos Martins, Domingos Martins, Espírito Santo, Brazil
Received: Apr. 23, 2019;       Accepted: Jun. 5, 2019;       Published: Jun. 20, 2019
DOI: 10.11648/j.cnn.20190302.13      View  120      Downloads  16
Abstract
Oligodendroglioma is a rare form of primary brain tumor, accounting for about 2-5% of intracranial tumors, being more common in adult males but rare in children, accounting for about 1-2% of all primary brain tumors in children. It originates from oligodendrocytes or glial precursor cells and exhibits infiltrative and slow growth. They can be classified in two grades (Grade II and Grade III), where Grade II are low grade tumors and have tumor cells that grow slowly and invade nearby normal tissue, and Grade III are malignant and have rapidly growing tumors. It has low growth and 50-80% of cases first symptom is seizures. A seizure is a symptom that requires a rapid solution usually requiring empirical treatment at the initial time to cease seizures and promote some well-being for the patient's routine. Seizures can cause a lot of damage to the patient's life, especially if the patient is a child who does not know what to do and what to do. Depending on the intensity and frequency of seizure episodes, the patient may experience fractures with falls, may suffer discrimination and prejudice at school. The causes behind refractory epilepsy are diverse, so whenever a patient is found to be refractory to drug treatment, the origin of seizures should be investigated early, it is not enough to stop at empirical treatment.
Keywords
Olingodendroglioma, Refractory Epilepsy, Primary Brain Tumors
To cite this article
Mauricio Vaillant Amarante, Ozinelia Pedroni Batista, Camilia Lampier Lutzke, Shirley Kempin Quiqui, Patient with Refractory Epilepsy Associated with Oligondendroglioma, Clinical Neurology and Neuroscience. Vol. 3, No. 2, 2019, pp. 43-45. doi: 10.11648/j.cnn.20190302.13
Copyright
Copyright © 2019 Authors retain the copyright of this article.
This article is an open access article distributed under the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/) which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Reference
[1]
MORENO-JIMENEZ, Sergio et al. Oligodendrogliomas en el Instituto Nacional de Neurología y Neurocirugía: comportamiento biológico en una población definida. Arch. Neurocien. (Mex., D.F.) [online]. 2005, vol.10, n.3, pp.140-145.. ISSN 0187-4705.
[2]
Barbashina V, Salazar P, Holland EC, Rosenblum MK, Ladanyi M (1 February 2005). "Allelic losses at 1p36 and 19q13 in gliomas: correlation with histologic classification, definition of a 150-kb minimal deleted region on 1p36, and evaluation of CAMTA1 as a candidate tumor suppressor gene". Clin. Cancer Res. 11 (3): 1119–28. PMID 15709179.
[3]
Ducray F, Idbaih A, de Reyniès A, et al. (2008). "Anaplastic oligodendrogliomas with 1p19q codeletion have a proneural gene expression profile". Mol. Cancer. 7: 41. doi: 10.1186/1476-4598-7-41. PMC 2415112. PMID 18492260.
[4]
Louis D, Ohgaki H, Wiestler O, et al. (2007). "The 2007 WHO Classification of Tumours of the Central Nervous System". Acta Neuropathologica. 114 (2): 97–109. doi: 10.1007/s00401-007-0243-4. PMC 1929165. PMID 17618441.
[5]
Hamlat A, Saikali S, Chaperon J, et al. (November 2005). "Oligodendroglioma: clinical study and survival analysis correlated with chromosomal anomalies". Neurosurg Focus. 19 (5): E15. doi:10.3171/foc.2005.19.5.16. PMID 16398465.
[6]
Lassman, A. B. (20 May 2009). "Retrospective analysis of outcomes among more than 1,000 patients with newly diagnosed anaplastic oligodendroglial tumors". Journal of Clinical Oncology. 27 (15S): 2014. doi: 10.1200/jco.2009.27.15s.2014 (inactive 2019-02-12). ISSN 0732-183X.
[7]
Sunyach MP, Jouvet A, Perol D, et al. (December 2007). "Role of exclusive chemotherapy as first line treatment in oligodendroglioma". J. Neurooncol. 85 (3): 319–28. doi: 10.1007/s11060-007-9422-3. PMID 17568995.
[8]
Ohgaki H, Kleihues P (June 2005). "Population-based studies on incidence, survival rates, and genetic alterations in astrocytic and oligodendroglial gliomas". J Neuropathol Exp Neurol. 64 (6): 479–489. doi:10.1093/jnen/64.6.479. PMID 15977639.
[9]
Feigenberg SJ, Amdur RJ, Morris CG, Mendenhall WM, Marcus RB, Friedman WA (2003). "Oligodendroglioma: does deferring treatment compromise outcome?". Am. J. Clin. Oncol. 26 (3): 60–66. doi: 10.1097/01.COC.0000072507.25834.D6. PMID 12796617.
[10]
Brainer-Lima PT,, Mertens Brainer-Lima A, Rocha Azevedo-Filho H. Ganglioglioma: comparison with other low-grade brain tumors. Arq. Neuro-Psiquiatr. 64 (3a): 613-618. doi: 10.1590/S0004-282X2006000400018.
[11]
Huang CI, Chiou WH, Ho DM (December 1987). "Oligodendroglioma occurring after radiation therapy for pituitary adenoma". Journal of Neurology, Neurosurgery & Psychiatry. 50 (12): 1619–24. doi: 10.1136/jnnp.50.12.1619. PMC 1032603. PMID 3325615.
[12]
Laigle-Donadey F, Benouaich-Amiel A, Hoang-Xuan K, Sanson M (2005). "[Molecular biology of oligodendroglial tumors]". Neuro-Chirurgie (in French). 51 (3–4 Pt 2): 260–8. doi: 10.1016/s0028-3770 (05)83487-3. PMID 16292170.
[13]
Walker C, Haylock B, Husband D, et al. (2006). "Clinical use of genotype to predict chemosensitivity in oligodendroglial tumors". Neurology. 66 (11): 1661–7. doi: 10.1212/01.wnl.0000218270.12495.9a. PMID 16769937.
[14]
Sérgio Reis Filho, J., et al. Oligodendrogliomas: estudo anatomopatológico e clínico de 15 casos. Arq. Neuro-Psiquiatr. 57 (2A): 249-54. doi: 10.1590/S0004-282X1999000200013 . PMID:10412525.
[15]
Agapejev S., et al. Oligodendroglioma cístico e positividade das reações para cisticercose relato de caso. Arq. Neuro-Psiquiatr. 50 (2): 234-38. doi: 10.1590/S0004-282X1992000200020.
[16]
Marques-Assis L, Guenni-Bejar D, Faria Lins Evaldo J. A epilepsia nos tumores cerebrais. Arq Neuro-Psiquiatr. 27 (1): 31-40. doi: 10.1590/S0004-282X1969000100002.
[17]
Souza Barboza E, et al. Meningeoma pós-radioterapia. Arq. Neuro-Psiquiatr. 64 (3b): 794-797. doi: 10.1590/S0004-282X2006000500017.
[18]
Reyes-Botero, Germán, Naranjo, Luis Fermín, Tobón, Vladimir, Franco, César, Álvarez, Juan Felipe, & Barrientos, Hernán. (2017). Uso de anticonvulsivantes en epilepsia secundaria a gliomas en adultos: serie de casos. Acta Neurológica Colombiana, 33 (3), 148-153. https://dx.doi.org/10.22379/24224022149.
[19]
Ramos, Tiago D. P., & Amorim, Lidia M. F.. (2015). Molecular biology techniques for loss of heterozygosity detection: the glioma example. Jornal Brasileiro de Patologia e Medicina Laboratorial, 51 (3), 189-196. https://dx.doi.org/10.5935/1676-2444.20150033.
[20]
Abrigo JM, Fountain DM, Provenzale JM, Law EK, Kwong JSW, Hart MG, Tam WWS. Magnetic resonance perfusion for differentiating low‐grade from high‐grade gliomas at first presentation. Cochrane Database of Systematic Reviews 2018, Issue 1. Art. No.: CD011551. DOI: 10.1002/14651858.CD011551.pub2.
[21]
Sarmiento JM, Venteicher AS, Patil CG. Early versus delayed postoperative radiotherapy for treatment of low‐grade gliomas. Cochrane Database of Systematic Reviews 2015, Issue 6. Art. No.: CD009229. DOI: 10.1002/14651858.CD009229.pub2.
Browse journals by subject